Two Paths: Device Reforms In Senate, House Bills Differ Dramatically
This article was originally published in The Gray Sheet
Executive Summary
Companies should expect much more in the way of FDA reforms than what is contained in the core user fee agreements. The chart compares provisions in the latest available versions of House and Senate bills.